Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

Amgen (NASDAQ:AMGN) announced new data supporting its FDA-approved osteoporosis therapy Prolia (Denosumab) on Monday, highlighting its potential against oral alendronate, a commonly-used medication to ...

The Food and Drug Administration has approved Fresenius Kabi's Biologics License Application for the denosumab biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht). These denosumab ...

Delaying doses of denosumab after the first injection dramatically boosts the risk that patients with osteoporosis will suffer vertebral fractures, a new study confirms. Physicians say they are ...

The FDA said it's looking into the risk of severe hypocalcemia among patients on dialysis receiving denosumab (Prolia), citing the potential for severe outcomes, including hospitalization and death.

SLM@lutheran-jamestown.org. Question: My new doctor says that my Prolia shot will be very expensive. When my previous physician gave me the shot it was covered in full. Why the difference in cost?

Findings showed denosumab-qbde demonstrated comparable quality, efficacy, safety, and immunogenicity to the reference product. Enoby is approved to treat postmenopausal women with osteoporosis at high ...

Please provide your email address to receive an email when new articles are posted on . Denosumab is associated with a greater increase in lumbar spine bone mineral density at 12 months compared with ...